This study aims to compare the risk of metabolic syndrome associated with long-term risperidone therapy versus olanzapine in patients with chronic schizophrenia.
Conducted a cross-sectional assessment of patients exposed to risperidone for an extended period.
Evaluated metabolic syndrome risk in comparison to olanzapine-treated patients.
Recommended regular metabolic monitoring and interventions for high-risk individuals.
Long-term risperidone therapy is linked to a lower risk of metabolic syndrome compared to olanzapine.
Regular metabolic monitoring is advised for patients on risperidone, especially those at high risk.
Abstract
Long-term risperidone therapy is associated with a lower MetS risk than olanzapine. Regular metabolic monitoring and adjunctive interventions are recommended for high-risk patients.